Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 29, 2015 5:57 AM ET

Biotechnology

Company Overview of Genelux Corporation

Company Overview

Genelux Corporation, a biomedical company, develops diagnostic and therapeutic solutions for cancer and inflammatory diseases. Its product GL-ONC1 is a genetically stable oncolytic virus strain to locate, enter, colonize, and destroy cancer cells without harming healthy tissues or organs. Genelux Corporation was founded in 2001 and is headquartered in San Diego, California. The company has locations in Redlands, California; and Bernried, Germany.

3030 Bunker Hill Street

Suite 300

San Diego, CA 92109 5754

United States

Founded in 2001

Phone:

858-483-0024

Fax:

858-483-0026

Key Executives for Genelux Corporation

Chief Executive Officer, President, Chief Compliance Officer and Director
Founder, Chairman Emeritus and Chief Scientific Advisor To The Chief Executive Officer
Chief Financial Officer
Age: 53
Chief Operating Officer, Director, Member of Scientific Advisory Board and Member of Clinical Advisory & Implementation Board
Chief Executive Officer of Genelux Europe and President of Genelux Europe
Compensation as of Fiscal Year 2015.

Genelux Corporation Key Developments

Genelux Corporation Announces Two Phase I Trials of GL-ONC1 in Head & Neck Cancer and Mesothelioma

Genelux Corporation announced that data from two Phase I trials evaluating its lead oncolytic virotherapy GL-ONC1 in head and neck cancer and malignant pleural mesothelioma demonstrate a favorable safety profile and support further investigation of the therapy in both indications. The results will be presented by lead investigators from Memorial Sloan Kettering Cancer Center and UC San Diego Moores Cancer Center at the upcoming 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29-June 2 in Chicago, IL. Data from the two Phase I trials are outlined. Abstract 6026 (Poster 349) Phase I trial of intravenous administration of attenuated vaccinia virus (GL-ONC1) with concurrent chemoradiotherapy (CRT) for locoregionally advanced head and neck carcinoma. The open-label, single-arm, dose-escalation study (NCT01584284) evaluated increasing doses of GL-ONC1 plus radiation and cisplatin in five cohorts of patients with late-stage disease (IVA or IVB), without reaching the maximum tolerated dose, indicating increased doses of GL-ONC1 may be feasible within the well-tolerated safety profile. Enrollment focused mostly on patients who have HPV-negative head and neck cancer, who are known to have poorer responses to standard of care than those with HPV-positive cancer.

Genelux Corporation Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 09:20 AM

Genelux Corporation Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 09:20 AM. Venue: Westin Grand Central Hotel, New York, New York, United States.

Genelux Announces Board Appointments

Genelux has appointed George Vandeman, long-time Amgen executive, and Thomas Zindrick, newly appointed Genelux President and CEO of Genelux, to the company's Board of Directors. Vandeman has also been named Vice Chairman and is the Board's fifth independent Director. Together, the appointments expand the Genelux Corp. Board to nine members.

Similar Private Companies By Industry

Company Name Region
NexImmune, Inc. United States
AzurRx BioPharma, Inc. United States
SKS Ocular, LLC United States
vTv Therapeutics LLC United States
Cordis Neurovascular, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Genelux Corporation, please visit www.genelux.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.